Taft Pharmaceutical & Life Sciences Litigation Chair Steve Auten will speak at the 21st Annual Paragraph IV Disputes Conference in New York City on April 29. The conference serves as a forum for Hatch-Waxman litigators and pharmaceutical patent practitioners to learn more about evolving policies, industry developments and trends, and litigation strategies.

Auten will participate in the roundtable discussion “Generic Pharma Roundtable and Breakout” at 3:45 p.m. ET. Speakers will cover insights on how generic companies can ensure portfolio sustainability, explore how traditionally generic companies are handling new identities as they transition into the branded and large molecule market through acquisitions, discuss the potential for more litigation as companies develop, and more.

For more information or to register, click here.

Auten is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators, and others on his LinkedIn blog “Hatch Waxman ANDA Litigation Forum” or HALF, which has over 14,000 members worldwide. He regularly represents clients in the areas of Paragraph IV design strategies, Hatch-Waxman litigation, and biosimilar market opportunities.